Natco Pharma closed the subscription period for its ₹12,794 million rights issue on October 22, 2026. The company initiated this capital raise to strengthen its balance sheet, with the issue window running from October 12 to October 22, 2026.

The Board of Directors approved the terms of the issuance on September 25, 2026. The offer comprised equity shares with a face value of ₹2 each, issued at a premium price of ₹750 per share. This corporate action was undertaken in compliance with the Companies Act, 2013, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Issue Structure and Timeline

The rights issue was structured as a cash-based offering for existing shareholders. The specific parameters of the issuance are outlined below:

The company confirmed the closure of the issue period in a filing to BSE and National Stock Exchange of India. Ch. Venkat Ramesh, Company Secretary and Compliance Officer, signed the intimation on October 22, 2026.

Regulatory Compliance

Natco Pharma stated that the issuance adhered to all applicable laws and regulations governing capital markets in India. The board approval preceded the opening of the issue by approximately two weeks, ensuring adequate time for regulatory filings and shareholder communication prior to the subscription window.

Natco Pharma announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market on October 19, 2026. The launch is executed by its wholly owned subsidiary, Natco Pharma USA LLC, in collaboration with Teyro Labs Pvt Ltd based in Chennai. This move aims to address a critical supply shortage of the drug in the United States.

Product indications and market size

Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma. Its clinical applications include first-line combination therapy and palliative treatment for recurrent disease following prior chemotherapy. According to industry sales data, the product recorded estimated sales of $27.8 million in the U.S. for the 12 months ending June 2026.

Strategic context for oncology portfolio

Natco Pharma operates as a research and development oriented entity with a strong focus on oncology. The company maintains nine manufacturing sites and two R&D facilities in India, with approvals from regulatory bodies including the US FDA, Brazil ANVISA, Health Canada, and WHO. These facilities support distribution across more than 50 global markets.

What the numbers show

The disclosed estimated sales figure of $27.8 million for the trailing 12 months provides a baseline for the addressable market Natco is entering. By launching a generic version amidst a stated critical shortage, the company positions itself to capture immediate demand where supply constraints exist. The collaboration with Teyro Labs leverages external manufacturing capacity, allowing Natco to expand its oncology footprint without necessarily expanding its own immediate production overheads for this specific molecule.